Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affe…

Lymphoma, Large B-Cell, Diffuse

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06890884

Phase 1

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). …

Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07519772

Phase 1

BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell …

Lymphoma, Non-HodgkinB-cell LymphomaLymphoma, Large B-Cell, Diffuse+4 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07101328

Phase 1

A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients w…

Lymphoma, B-CellLymphoma, Non-Hodgkin (NHL)Lymphoma, Large B-Cell, Diffuse (DLBCL)+1 more

Estimated

~$10 – $8,750

Umoja BiopharmaNCT06528301

Phase 2

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a tre…

LymphomaLymphoma, Large B-Cell, Diffuse

Estimated

~$10 – $7,500

Jennifer Crombie, MDNCT05800366